Patents Assigned to Valneva
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20190290747
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: March 7, 2019
    Publication date: September 26, 2019
    Applicant: Valneva Austria GmbH
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 10357557
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: July 23, 2019
    Assignees: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • ZIKA VIRUS PURIFICATION
    Publication number: 20190008945
    Abstract: Described herein are improved purification methods for Zika virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering said Zika vaccines to subjects in need thereof.
    Type: Application
    Filed: December 23, 2016
    Publication date: January 10, 2019
    Applicant: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert SchlegI, Michael Weber, Jürgen Wruss
  • VIRUS PURIFICATION
    Publication number: 20180369359
    Abstract: Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika, Chikungunya, dengue and yellow fever vaccines and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: December 23, 2016
    Publication date: December 27, 2018
    Applicant: Valneva SE
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Wruss
  • ZIKA VIRUS VACCINE
    Publication number: 20180371027
    Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: December 23, 2016
    Publication date: December 27, 2018
    Applicant: Valneva Austria GmbH
    Inventors: Jana BARBERO CALZADO, Mario NEBENFÜHR, Robert SCHLGEL, Michael WEBER, Jürgen WRUSS
  • VIRUS PURIFICATION
    Publication number: 20180362937
    Abstract: Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.
    Type: Application
    Filed: December 23, 2016
    Publication date: December 20, 2018
    Applicant: Valneva SE
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Wruss
  • ZIKA VIRUS PURIFICATION
    Publication number: 20180362936
    Abstract: Described herein are processes for purifying infectious Zika virus particles and uses of protamine in such processes.
    Type: Application
    Filed: December 23, 2016
    Publication date: December 20, 2018
    Applicant: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Wruss
  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20180362593
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: April 4, 2018
    Publication date: December 20, 2018
    Applicant: Valneva Austria GmbH
    Inventors: Urban Lundberg, Wolfgang Schüler
  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20180327460
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: February 27, 2018
    Publication date: November 15, 2018
    Applicant: Valneva Austria GmbH
    Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
  • Apparatus for screening cells
    Patent number: 9977017
    Abstract: Provided are a method and means permitting the simultaneous measurement of the reactive properties of more than 10,000 of antigen-stimulated lymphocytes being held on a chip and the separate determination of the states of individual cells. A microwell array comprises multiple wells and a coating layer on one of the principal surfaces of a base member, the wells being of a size permitting the entry of only a single cell into each well. A coating layer of a substance capable of binding to a substance produced by the cells contained in the wells is present on the principal surface around the wells.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: May 22, 2018
    Assignees: TOYAMA PREFECTURE, VALNEVA
    Inventors: Aishun Jin, Hiroyuki Kishi, Atsushi Muraguchi, Tsutomu Obata
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 9975927
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: May 22, 2018
    Assignee: Valneva Austria GmbH
    Inventors: Urban Lundberg, Wolfgang Schüler
  • DUCK EMBRYONIC DERIVED STEM CELL LINES FOR THE PRODUCTION OF VIRAL VACCINES
    Publication number: 20180135026
    Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
    Type: Application
    Filed: October 17, 2017
    Publication date: May 17, 2018
    Applicant: Valneva
    Inventors: Fabienne Guehenneux, Karine Moreau, Magali Esnault, Majid Mehtali
  • ASEPTIC PURIFICATION PROCESS FOR VIRUSES
    Publication number: 20180119110
    Abstract: Described herein are processes for the purification of viruses and compositions thereof.
    Type: Application
    Filed: April 4, 2016
    Publication date: May 3, 2018
    Applicant: Valneva SE
    Inventors: Robert Schlegl, Michael Weber
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 9926343
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: March 27, 2018
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
  • Aluminum compounds for use in therapeutics and vaccines
    Patent number: 9913898
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminum and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminum content. The invention further relates to aqueous compositions comprising a protein and an aluminum-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: March 13, 2018
    Assignee: Valneva Austria GmbH
    Inventors: Robert Schlegl, Michael Möhlen, Jürgen Wruss, Michael Weber
  • Aluminum compounds for use in therapeutics and vaccines
    Patent number: 9895437
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminum and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminum content. The invention further relates to aqueous compositions comprising a protein and an aluminum-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: February 20, 2018
    Assignee: Valneva Austria GmbH
    Inventors: Robert Schlegl, Michael Möhlen, Jürgen Wruss, Michael Weber
  • Aluminum compounds for use in therapeutics and vaccines
    Patent number: 9884115
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: February 6, 2018
    Assignee: Valneva Austria GmbH
    Inventors: Robert Schlegl, Michael Möhlen, Jürgen Wruss, Michael Weber
  • Method of making a virus using duck embryonic derived stem cell lines
    Patent number: 9822345
    Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: November 21, 2017
    Assignee: Valneva
    Inventors: Fabienne Guehenneux, Karine Moreau, Magali Esnault, Majid Mehtali
  • ALUMINUM COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES
    Publication number: 20170296656
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Application
    Filed: March 27, 2017
    Publication date: October 19, 2017
    Applicant: Valneva Austria GmbH
    Inventors: ROBERT SCHLEGL, Michael Möhlen, Jürgen Wruss, Michael Weber
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20170239340
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 24, 2017
    Applicants: Valneva Austria GmbH, Intercell USA, Inc.
    Inventors: LARRY R. ELLINGSWORTH, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig